Nerandomilast's tolerability and dual antifibrotic/immunomodulatory mechanism directly address the critical non-adherence ...
Nerandomilast, a novel anti-fibrotic agent with improved tolerability and a dual antifibrotic/immunomodulatory mechanism, ...
Pharmaceutical Technology on MSN
Boehringer’s Jascayd gains China’s NMPA approval for PPF
China’s National Medical Products Administration (NMPA) has granted approval for Boehringer Ingelheim’s Jascayd ...
Ingelheim: Boehringer Ingelheim has announced that China's National Medical Products Administration (NMPA) has approved ...
Nerandomilast is an oral, preferential PDE4B inhibitor approved in China for the treatment of adult patients with IPF and PPF. It was also approved by the U.S. Food and Drug Administration (FDA) for ...
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years.PPF is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback